[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:apolipoprotein-a":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Apolipoprotein(a)",10,8,[8,16,22,29,35,41,47,53,59,66],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07327840","Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:50.548894Z","2026-07-05T03:45:20.248611Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06496243","Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.478056Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07157774","Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)",[26],"Phase 3","2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.323863Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05646381","A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:29.048407Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06813911","Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD",[26],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.963810Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07136012","OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events",[26],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:28.653489Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06494501","The Prevent Coronary Artery Disease Trial",[26],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:27.744105Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06439654","Atlantic Lipid Lowering Treatment Optimization Program",[],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:26.681995Z",{"nct_id":60,"title":61,"phases":62,"status":63,"updated_at":64,"content_modified":65},"NCT07198009","2-HOBA Supplementation in People With Elevated Lipoprotein(a)",[],"NOT_YET_RECRUITING","2026-08-26T02:18:30.351130Z","2026-05-05T02:43:29.739173Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT07235046","A Study of DII235 in Adults With Elevated Lipoprotein(a)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:07:36.529363Z","2026-05-05T02:43:28.222408Z"]